Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 juil. 2023 16h00 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful...
Arcutis to Present at Upcoming Investor Conference
06 juin 2023 16h00 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in...
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 juin 2023 16h00 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful...
Arcutis Announces Leadership Transition
24 mai 2023 17h00 HE
|
Arcutis Biotherapeutics, Inc.
Senior Vice President and Chief Commercial Officer (CCO) Ken Lock Stepping DownAyisha Jeter Appointed Interim CCO WESTLAKE VILLAGE, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics,...
Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update
09 mai 2023 16h02 HE
|
Arcutis Biotherapeutics, Inc.
Achieved net revenues of $2.8 million for ZORYVE® (roflumilast) cream 0.3% in the first quarter of 2023, with unit demand growth nearly doubling quarter-over-quarterContinued expansion of commercial...
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 mai 2023 16h00 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., May 05, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful...
Arcutis Completes Enrollment in INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
02 mai 2023 08h00 HE
|
Arcutis Biotherapeutics, Inc.
A total of 652 children, ages 2 to 5, were enrolled in the studyTopline data expected in the third quarterAtopic dermatitis (AD) affects approximately 26 million adults and children in the United...
Arcutis Announces Canadian Approval of ZORYVE™ (roflumilast) Cream 0.3% for Treatment of Plaque Psoriasis in Individuals 12 Years and Older
28 avr. 2023 16h01 HE
|
Arcutis Biotherapeutics, Inc.
First novel steroid-free topical with a new mechanism of action approved for plaque psoriasis in over 25 yearsFirst ZORYVE approval outside of the U.S. marks key milestone for Arcutis WESTLAKE...
Arcutis to Report First Quarter Financial Results
25 avr. 2023 16h00 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful...
Arcutis Announces FDA Acceptance of New Drug Application for Roflumilast Foam 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
18 avr. 2023 08h00 HE
|
Arcutis Biotherapeutics, Inc.
FDA has set a target action date of December 16, 2023NDA supported by positive efficacy and safety data from the Phase 2 and pivotal Phase 3 trials of roflumilast foamIf approved, roflumilast foam...